The Journal of Clinical Psychiatry

Author Index to Volume 71: January 2010 Through December 2010

Aarre TF see Rosa AR
Aarsland D see Testad I
Abad JMH see Borges G
Abrams K see Cosci F
Adams DH see Perlis RH
Adler LA. Monitoring adults with ADHD: a focus on executive and behavioral function. Aug e18
Adler LA see Winhusen TM
Adli M see Seemüller F; Wiethoff K
Agambaram V see McElroy SL
Aguiar B see de Lucena D
Ahima RS see Cizza G
Ahnemark E see Jokinen J
Ahola K see Virtanen M
Akbaraly TN see Singh-Manoux A
Alegría AA, Hasin DS, Nunes EV, Liu S-M, Davies C, Grant BF, Blanco C. Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Sept 1187–1195
Alegría AA see Blanco C
Aleman A see Dlabač-de Lange JJ
Alexopoulos GS. Psychotherapy for late-life depression. June e13
Allerup P see Baandrup L
Alonso J see Borges G
Alphs LD see Meyer RE
Alter CL see West JC
Altshuler LL. Reply to Sparhawk R: Antidepressants in bipolar disorder: caveats in interpreting and applying the findings of Altshuler et al [letter]. Feb 212
Altshuler LL see Post RM
Alvarez-Jimenez M see Gleeson JFM
Ameli R see DiazGranados N
Amminger GP see Henry LP
Ancelin M-L see Scali J
Andersson G see Cuijpers P
Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. Dec 1565–1575
Andrade LH see Borges G
Andreassen OA see Berg AO
Andres F-J see Bundy BD
Angermeyer MC see Borges G
Anghelescu I see Zeugmann S
Ankri J see Singh-Manoux A
Annweiler C see Richard-Devantoy S
Ansell EB see Grilo CM
Aparasu RR see Mehta S
Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano H, Maeda J, Okubo Y, Suhara T. Positron emission tomography measurement of dopamine D_2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. Sept 1131–1137
Arakawa R see Saijo T
Arango C see Bobes J; Rapado-Castro M
Arlinde CM see Bejerot S
Arnold LE see Findling RL; Horwitz SM
Arria AM see Garnier LM
Arts B see Jabben N
Åsberg M see Jokinen J
Asmundson GJG see McMillan KA
Ataoglu A see Canan F
Attiullah N see Zimmerman M
Axelson D see Findling RL; Horwitz SM
Axelson DA see Sala R
Baandrup L, Allerup P, Nordentoft M, Lublin H, Glenthoj BY. Exploring regional variation in antipsychotic coprescribing practice: a Danish questionnaire survey. Nov 1457–1464
Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. Feb 103–108
Baeza I see Rapado-Castro M
Baghai TC see Wiethoff K
Bai F see Yuan Y
Bai Y-M see Lin C-C
Bailey L see Valdovinos MG
Bailine SH see Smith GE
Baker AL, Hides L, Lubman DI. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. Mar 247–254
Baker RA see Kemp DE
Baker RW see Marder SR
Balanzá V see Vieta E
Balasubramanyam V see Kunik ME
Baldassano CF see Ghaemi SN
Baldessarini RJ. Review of Iverson LL, Iverson SD, Bloom FE, Roth RH: *Introduction to Neuropsychopharmacology.* Oct 1405–1406
Baldessarini RJ see Ghaemi SN
Ballard C see Testad I
Bannon Y see Sheehan DV
Barkley RA. Differential diagnosis of adults with ADHD: the role of executive function and self-regulation. July e17
Barr AM see Procyshyn RM
Barsky AJ see Sakai R
Batty GD see Virtanen M
Bauer M see Seemüller F; Wiethoff K; Young AH
Baylé FJ see Kasper S
Beasley CM Jr see Meyer RE
Beauchet O see Richard-Devantoy S
Beautrais A see Borges G
Beautrais AL see Meyer RE
Bech P, Lönn SL, Overø KF. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder. Feb 121–129
Beckham JC see Green KT
Beekman ATF see Lamers F; Vogelzangs N
Bejerot S, Rydén EM, Arlinde CM. Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study. Dec 1590–1597
Bélanger C see St-Jacques J
Bell CC. Review of Compton MT (ed): *Clinical Manual of Prevention in Mental Health.* Oct 1404–1405
Benca RM see Roth T
Bender DS see Grilo CM
Bender J Jr see Rodriguez CI
Bender W see Seemüller F
Ben-Ezra M, Soffer Y. Hospital personnel reactions to Haiti's earthquake: a preliminary matching study [letter]. Dec 1700–1701
Benjamin S. Review of Mendoza JE, Foundas AL: *Clinical Neuroanatomy: A Neurobehavioral Approach.* May 657–658
Benjelloun H see Peele R
Bennett M see Van Ameringen M
Berg AO, Melle I, Torjesen PA, Lien L, Hauff E, Andreassen OA. Cross-sectional study of vitamin D deficiency among immigrants and Norwegians with psychosis compared to the general population. Dec 1598–1604
Bergsholm P see Halmøy A
Berman BA, Duffy K, Serper MR. Beliefs about voices and aggressive behavior in inpatients in an acute psychiatric setting. Apr 497–501

Berner JE. Statins can produce ataxia in bipolar disorder: two case reports [letter]. Mar 359
Bernstein HJ see Smith GE
Berthier ML see Dávila G
Bertsch J see Rosa AR
Biederman J see Surman CBH
Birmaher B see Findling RL; Horwitz SM; Sala R
Bisaga A see Brooks AC
Blackman MR see Cizza G
Blanco C, Alegría AA, Petry NM, Grant JE, Simpson HB, Liu S-M, Grant BF, Hasin DS. Prevalence and correlates of fire-setting in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Sept 1218–1225
Blanco C, Okuda M, Markowitz JC, Liu S-M, Grant BF, Hasin DS. Epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Dec 1645–1656
Blanco C see Alegría AA; Oquendo MA
Bleijenberg G see The GKH
Blom JD see Slotema CW
Bobes J, Arango C, Garcia-Garcia M, Rejas J, CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. Mar 280–286
Bock T see Lambert M
Bockting CLH see ten Doesschate MC
Boerescu DA see Zimmerman M
Bogen DL, Hanusa BH, Moses-Kolko E, Wisner KL. Are maternal depression or symptom severity associated with breastfeeding intention or outcomes? Aug 1069–1078
Boggio PS, Rocha M, Oliveira MO, Fecteau S, Cohen RB, Campanhã C, Ferreira-Santos E, Meleiro A, Corchs F, Zaghi S, Pascual-Leone A, Fregni F. Noninvasive brain stimulation with high-frequency and low-intensity repetitive transcranial magnetic stimulation treatment for posttraumatic stress disorder. Aug 992–999
Boguslavsky I see Ritsner MS
Bombin I see Rapado-Castro M
Bond DJ see Torres IJ
Borges G, Nock MK, Abad JMH, Hwang I, Sampson NA, Alonso J, Andrade LH, Angermeyer MC, Beautrais A, Bromet E, Bruffaerts R, de Girolamo G, Florescu S, Gureje O, Hu C, Karam EG, Kovess-Masfety V, Lee S, Levinson D, Medina-Mora ME, Ormel J, Posada-Villa J, Sagar R, Tomov T, Uda H, Williams DR, Kessler RC. Twelve month prevalence of and risk factors for suicide attempts in the World Health Organization World Mental Health Surveys. Dec 1617–1628
Borrelli D see Ghaemi SN
Bossie CA see Canuso CM
Boter H, Derks EM, Fleischhacker WW, Davidson M, Kahn RS, EUFEST Study Group. Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). Jan 58–65
Bouchard S see St-Jacques J
Bowden CL. Diagnosis, treatment, and recovery maintenance in bipolar depression. Jan e01
Bowden CL. Treatment strategies for bipolar depression. May e10
Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. Feb 130–137
Bowden CL see Hirschfeld RMA
Boyle LL, Þorsteinsson AP, Cui X, King DA, Lyness JM. Depression predicts cognitive disorders in older primary care patients. Jan 74–79
Braw Y see Levkovitz Y
Brawman-Mintzer O see Stein MB
Brecher M see McElroy SL; Young AH
Breier A see Perlis RH
Brenes GA see Vogelzangs N
Brewin CR, Patel T. Auditory pseudohallucinations in United Kingdom war veterans and civilians with posttraumatic stress disorder. Apr 419–425
Bridge JA see Meyer RE
Brieger P see Seemüller F; Wiethoff K
Brigham GS see Winhusen TM
Brodziak K see Wilens TE
Broich K see Meyer RE
Bromet E see Borges G
Brønnick K see Testad I
Brooks AC, Comer SD, Sullivan MA, Bisaga A, Carpenter KM, Raby WM, Yu E, O'Brien CP, Nunes EV. Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment. Oct 1371–1378
Brown GK see Meyer RE
Bruffaerts R see Borges G
Brutsche NE see DiazGranados N
Buckley PF. Review of Faemi SH: *The Medical Basis of Psychiatry, 3rd ed.* Aug 1105
Buitelaar JK see The GKH
Bukstein OG see Goldstein BI
Bundy BD, Hewer W, Andres F-J, Gass P, Sartorius A. Influence of anesthetic drugs and concurrent psychiatric medication on seizure adequacy during electroconvulsive therapy. June 775–777
Burg MM see Martens EJ
Burger H see Laan W
Burke SJ see Tohen M
Burlon M see Lambert M
Bursztejn C see Greene MB
Bushe CJ see Holt RIG
Bussopulos A see Lambert M
Cahn W see Koolschijn PCMP
Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. Oct 1363–1370
Calabrese JR see Kemp DE
Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA. Cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. Mar 338–347
Caldeira KM see Garnier LM
Calhoun PS see Green KT
Campanhã C see Boggio PS
Canan F, Ataoglu A. Memantine-related psychotic symptoms in a patient with bipolar disorder [letter]. July 957
Canuso CM, Lindenmayer J-P, Kosik-Gonzalez C, Turkoz I, Carothers J, Bossie CA, Schooler NR. Randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. May 587–598
Caputo A see Stahl SM
Carlson JL see Marder SR
Carothers J see Canuso CM
Carpenter KM see Brooks AC
Carpenter LL see Yip AG
Carrière I see Scali J
Case M see Tohen M
Case MG see Houston JP
Castro-Fornieles J see Rapado-Castro M; Sala R
Cavazzoni PA see Marder SR
Chacón SJ see Dávila G
Chan AYY see Lam SP
Chan F see Rapoport MJ
Chan H-Y, Chiang S-C, Chang C-J, Gau SS-F, Chen J-J, Chen C-H, Hwu H-G, Lai M-S. Randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. Sept 1226–1233

Chan H-Y, Gau SS-F. Reply to Suzuki T: Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine? [letter] Nov 1554
Chang C-J see Chan H-Y
Chang KD. Course and impact of bipolar disorder in young patients. Feb e05
Chang T, Fava M. Future of psychopharmacology of depression. Aug 971–975
Chang W see McElroy SL; Young AH
Chavez B, Reilly T. Manic and psychotic symptoms following subcutaneous leuprolide in a male patient with no prior psychiatric history [letter]. Dec 1696–1698
Chelminski I see Zimmerman M
Chen C-C see Kuo C-J
Chen C-H see Chan H-Y
Chen C-M see Wu C-C
Chen H see Mehta S
Chen H-C see Hwang T-J
Chen J-J see Chan H-Y
Chen J-Y see Lin C-C
Chen T-T see Lin C-C
Chethan KB see Andrade C
Cheung AH see Sinyor M
Chiang P-T see Hou W-H
Chiang S-C see Chan H-Y
Chiles C. Review of Roberts LW, Hoop JG (eds): *Professionalism and Ethics: Q & A Self-Study Guide for Mental Health Professionals.* Apr 510
Chiles C. Review of Virani AS, Bezchlibnyk-Butler KZ, Jeffries JJ (eds): *Clinical Handbook of Psychotropic Drugs.* May 658
Chirazi-Stark MS see Lambert M
Chirieac MC see Gracious BL
Chiu H-W see Lin C-C
Chiu S-Y see Hou W-H
Cholongitas E, Pipili C. Impact of burnout syndrome on gastroesophageal reflux disease and irritable bowel syndrome in health care workers [letter]. Feb 209–210
Chouinard G see Corruble E
Chu NF see Surman CBH
Citrome L, Moss SV. How to efficiently maintain your own electronic resource library [ASCP Corner]. Feb 207–208
Cizza G, Nguyen VT, Eskandari F, Duan Z, Wright EC, Reynolds JC, Ahima RS, Blackman MR, POWER Study Group. Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study. Aug 1079–1087
CLAMORS Study Collaborative Group see Bobes J
Clark CP. Review of Lee-Chiong T Jr: *Sleep Medicine: Essentials and Review.* June 810–811
Clayton PJ. V code for bereavement [letter with reply]. Mar 359–360
Clayton PJ see Meyer RE
Cobaleda S see Vieta E
Cohen LS see Freeman MP
Cohen RB see Boggio PS
Coleman CI see Ehret M
Collins M see Hirschfeld RMA
Colom F. Achieving remission and recovery in bipolar disorder. Nov e32
Comer SD see Brooks AC
Compton MT, Goulding SM, Walker EF. Characteristics of the retrospectively assessed prodromal period in hospitalized patients with first-episode nonaffective psychosis: findings from a socially disadvantaged, low-income, predominantly African American population. Oct 1279–1285
Conley RR see Kelly DL
Cook SR see Gracious BL
Corchs F see Boggio PS
Cordes J see Wiethoff K
CORE Investigators see Smith GE
Correll CU. Symptomatic presentation and initial treatment for schizophrenia in children and adolescents. Nov e29
Correll CU. Understanding schizoaffective disorder: from psychobiology to psychosocial functioning. Suppl 2, 8–13
Correll CU see Kane JM
Corruble E, Gorwood PAPM, Chouinard G. Reply to Clayton PJ: V code for bereavement [letter]. Mar 360
Cortez V see López-Jaramillo C
Cosci F, Knuts IJE, Abrams K, Griez EJL, Schruers KRJ. Cigarette smoking and panic: a critical review of the literature. May 606–615
Cotton SM see Gleeson JFM
Covey LS see Winhusen TM
Cowperthwait C see Perlis RH
Creech RS see McElroy SL
Crews MPK, Dhillon GS, MacCabe JH. Clozapine rechallenge following clozapine-induced pericarditis [letter]. July 959–961
Crisp K see Gleeson JFM
Croghan IT see Winhusen TM
Cruz N see Rosa AR
Crystal S see West JC
Cui X see Boyle LL
Cuijpers P, van Straten A, van Oppen P, Andersson G. Comparing psychotherapy and pharmacotherapy for adult depression: adjusting for differential dropout rates [letter]. Sept 1246
Cullum CM see Smith GE
Culpepper L. Evaluating the patient with fibromyalgia. Sept e25
Culpepper L. Nonpharmacologic care of patients with fibromyalgia. Aug e20
Culpepper L. Recognizing and diagnosing fibromyalgia. Nov e30
Culpepper L. Why do you need to move beyond first-line therapy for major depression? Suppl 1, 4–9
Culpepper L see Podawiltz A
Currier D see Oquendo MA
Dalrymple K see Zimmerman M
Dartigues J-F see Scali J
David D see Szentagotai A
Davidson JRT. Major depressive disorder treatment guidelines in America and Europe. Suppl E1, e04
Davidson JRT see Nutt DJ
Davidson M see Boter H
Davies C see Alegría AA
Dávila G, Berthier ML, Kulisevsky J, Chacón SJ. Suicide and attempted suicide in Tourette's syndrome: a case series with literature review [letter]. Oct 1401–1402
Davila JA see Kunik ME
Dawe IC see Marder SR
de Arce R see Vieta E
de Brito NFC see Prazeres AM
DeFreitas CM see Torres IJ
DeFreitas VG see Torres IJ
Degenhardt EK see Houston JP
de Girolamo G see Borges G
de Jonge P see Lamers F
DelBello MP see Strawn JR
de Leon J, Diaz FJ, Spina E. Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied [letter with reply]. July 957–958
Deligiannidis KM. Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium [ASCP Corner]. May 649–650
Dellva MA see Marder SR
DELTA Study Group see ten Doesschate MC
de Lucena D, Fernandes BS, Kunz M, Fries GR, Stertz L, Aguiar B, Pfaffenseller B, Gama CS. Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine [letter]. Jan 91–92
de Mathis MA see Prazeres AM
Demeter CA see Findling RL; Horwitz SM
den Boer JA see van Apeldoorn FJ
Dennehy EB see Perlis RH
Dennis MF see Green KT
Denollet J see Martens EJ
Depew J see Findling RL
de Quervain DJ-F see Kolassa I-T

Derks EM see Boter H
de Ruiter MB see Thomaes K
Dhillon GS see Crews MPK
Diaz FJ see de Leon J
DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate CA Jr. Rapid resolution of suicidal ideation after a single infusion of an *N*-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. Dec 1605–1611
Dickstein D see Sala R
Diniz JB see Prazeres AM
Dlabač-de Lange JJ, Knegtering R, Aleman A. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. Apr 411–418
Doody RS see Kunik ME
Dorer EM see Winhusen TM
Dorey J-M see Richard-Devantoy S
Dorrepaal E see Thomaes K
Doshi JA see Olfson M
Dowlati Y see Sinyor M
Draganac-Cardona L see Waxmonsky JG
Draijer N see Thomaes K
Draisma S see van Zaane J
Dramsdahl M see Halmøy A
D'Souza DC see Kane JM
Duan Z see Cizza G
Duffy K see Berman BA
Duivenvoorden H see Ingenhoven T
Dunayevich E see Marder SR
Dunner DL. Review of Labbate LA, Fava M, Rosenbaum JF, Arana GW: *Handbook of Psychiatric Drug Therapy.* Oct 1404
Dunner DL. Review of Wynn GH, Oesterheld JR, Cozza KL, Armstrong SC: *Clinical Manual of Drug Interaction: Principles for Medical Practice.* July 962–963
Durell TM see Tohen M
Dyck IR see Eisen JL
Eckart C see Kolassa I-T
Ehret M, Goethe J, Lanosa M, Coleman CI. Effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. Oct 1286–1292
Eisen JL, Pinto A, Mancebo MC, Dyck IR, Orlando ME, Rasmussen SA. 2-year prospective follow-up study of the course of obsessive-compulsive disorder. Aug 1033–1039
Elbert T see Kolassa I-T
Elhai JD see Richardson JD
El-Mallakh RS see Ghaemi SN
Elovainio M see Virtanen M
Elsik M see Ronaldson KJ
EMBOLDEN I (Trial 001) Investigators see Young AH
EMBOLDEN II (Trial D1447C00134) Investigators see McElroy SL
Emmelkamp PMG see van Oppen P
Engel RR see Stübner S
Enns MW see McMillan KA
Epperson CN see Forray A
Erman M see Roth T
Ertl V see Kolassa I-T
Eskandari F see Cizza G
Eudicone JM see Kemp DE
EUFEST Study Group see Boter H
European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Advisory Board see Tohen M
Falk DM see Marder SR
Fallgatter AJ see Fischer M
Faraone SV, Glatt SJ. Comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. June 754–763
Faraone SV see Surman CBH; Weiss MD
Farmen M see Perlis RH
Farrelly SE see Henry LP
Fasmer OB see Halmøy A
Fatemi HS. Review of Mueser KT, Jeste DV (eds): *Clinical Handbook of Schizophrenia.* July 962
Faulkner LR, Vondrak PA. Frequently asked questions about maintenance of certification (MOC) [commentary]. May 632–633
Fava GA, Porcelli P, Rafanelli C, Mangelli L, Grandi S. Spectrum of anxiety disorders in the medically ill. July 910–914
Fava M. Switching treatments for complicated depression. Feb e04
Fava M. Using complementary and alternative medicines for depression. Sept e24
Fava M, Mischoulon D. Evidence for folate in combination with antidepressants at initiation of therapy. Nov e31
Fava M see Chang T; Freeman MP; Stahl SM
Fawcett RG. Acute psychosis associated with anti–NMDA-receptor antibodies and bilateral ovarian teratomas: a case report [letter]. Apr 504
Fecteau S see Boggio PS
Feinstein A see Rapoport MJ
Fellows I see Zisook S
Felmlee-Devine MD see Smith GE
Fennig S see Levkovitz Y
Fernandes BS see de Lucena D
Ferrão YA see Prazeres AM
Ferreira-Santos E see Boggio PS
Ferrie JE see Singh-Manoux A
Fields B see Findling RL
Fijal B see Perlis RH
Filkowski MM see Ghaemi SN
Findling RL, Youngstrom EA, Fristad MA, Birmaher B, Kowatch RA, Arnold LE, Frazier TW, Axelson D, Ryan N, Demeter CA, Gill MK, Fields B, Depew J, Kennedy SM, Marsh L, Rowles BM, Horwitz SM. Characteristics of children with elevated symptoms of mania: the Longitudinal Assessment of Manic Symptoms (LAMS) study. Dec 1664–1672
Findling RL see Horwitz SM
Fineberg NA see Hollander E
Fink M see Smith GE
Fink-Jensen A see Baandrup L
Finucane TL see Gracious BL
Fischel SV see Liptzin B
Fischer M, Reif A, Polak T, Pfuhlmann B, Fallgatter AJ. False-positive methadone drug screens during quetiapine treatment [letter]. Dec 1696
Fischetti AT see Gracious BL
Fisher R see Wiethoff K
Fitzgerald PB see Ronaldson KJ
Fleischhacker WW see Boter H
Florescu S see Borges G
Focseneanu M see Forray A
Fontenelle LF see Prazeres AM
Ford CV. Review of Conrad P: *The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders.* Apr 508–509
Forray A, Focseneanu M, Pittman B, McDougle CJ, Epperson CN. Onset and exacerbation of obsessive-compulsive disorder in pregnancy and the postpartum period. Aug 1061–1068
Forslund K see Jokinen J
Foucher J see Greene MB
Foy D see Morland LA
Fraguas D see Rapado-Castro M
Franco C see Rosa AR
Frank J see Greene MB
Frazier TW see Findling RL; Horwitz SM
Freeman AM III. Review of Yalom ID: *Staring at the Sun: Overcoming the Terror of Death.* Jan 94–95
Freeman MP, Fava M, Lake J, Trivedi MH, Wisner KL, Mischoulon D. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force Report. June 669–681
Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. June 682–688
Freeman MP see Gelenberg AJ
Fregni F see Boggio PS
Freudenreich O see Goff DC

Friedman JH. Tardive dystonia due to aripiprazole use in a neuroleptic-naive patient [letter]. May 652–653
Friedman M see Zimmerman M
Frieling M see Lambert M
Fries GR see de Lucena D
Fristad MA see Findling RL; Horwitz SM
Frölich M see Vidarsdottir S
Frueh BC see Morland LA
Frye MA see Calabrese JR; Post RM
Fu K, Wong PWC, Yip PSF. What do Internet users seek to know about depression from Web searches? a descriptive study of 21 million Web queries [letter]. Sept 1246–1247
Gaebel W see Seemüller F
Gal G see Levkovitz Y
Galione JN see Zimmerman M
Gallarda T see Richard-Devantoy S
Gallo A see López-Jaramillo C
Gama CS see de Lucena D
García J see López-Jaramillo C
Garcia-Garcia M see Bobes J
Garnier LM, Arria AM, Caldeira KM, Vincent KB, O'Grady KE, Wish ED. Sharing and selling of prescription medications in a college student sample. Mar 262–269
Garré J-B see Richard-Devantoy S
Gass P see Bundy BD
Gasse C see Baandrup L
Gau SS-F see Chan H-Y
Gaudiano BA, Zimmerman M. Does comorbid posttraumatic stress disorder affect the severity and course of psychotic major depressive disorder? Apr 442–450
Gelenberg AJ. Complementary and alternative medicine in psychiatry [editorial]. June 667–668
Gelenberg AJ. Depression symptomatology and neurobiology. Jan e02
Gelenberg AJ. NCDEU's golden anniversary. July 820
Gelenberg AJ. Optimizing depression treatment to increase the likelihood of remission. Sept e22
Gelenberg AJ. Prevalence and impact of depression. Mar e06
Gelenberg AJ. Review of the current guidelines for depression treatment. July e15
Gelenberg AJ. Using assessment tools to screen for, diagnose, and treat major depressive disorder in clinical practice. Suppl E1, e01
Gelenberg AJ, Freeman MP. Tribute to *JCP*'s peer reviewers [editorial]. Jan 6–11
Gelenberg AJ, Thase ME. Performance improvement CME: improving outcomes in depression. Aug e19
Gelenberg AJ see Nutt DJ
Geracioti TD Jr see Strawn JR
Ghaemi SN, Ostacher MM, El-Mallakh RS, Borrelli D, Baldassano CF, Kelley ME, Filkowski MM, Hennen J, Sachs GS, Goodwin FK, Baldessarini RJ. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. Apr 372–380
Gibbins C see Weiss MD
Gibel A see Ritsner MS
Gilbertson MW, McFarlane AC, Weathers FW, Keane TM, Yehuda R, Shalev AY, Lasko NB, Goetz JM, Pitman RK, Harvard/VA PTSD Twin Study Investigators. Is trauma a causal agent of psychopathologic symptoms in posttraumatic stress disorder? findings from identical twins discordant for combat exposure. Oct 1324–1330
Gill MK see Findling RL; Horwitz SM; Sala R
Giltay EJ see van Reedt Dortland AKB
Girardi P see Manfredi G
Glatt SJ see Faraone SV
Glazer WM see Woods SW
Gleeson JFM, Cotton SM, Alvarez-Jimenez M, Wade D, Crisp K, Newman B, Spiliotacopoulos D, McGorry PD. Family outcomes from a randomized control trial of relapse prevention therapy in first-episode psychosis. Apr 475–483
Glenthoj BY see Baandrup L
Glöckner F see Kolassa I-T
Glorioso DK see Jin H
Goethe J see Ehret M
Goetz JM see Gilbertson MW
Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. Suppl 2, 20–26
Goldblatt MJ see Weinberg I
Goldstein BI, Bukstein OG. Comorbid substance use disorders among youth with bipolar disorder: opportunities for early identification and prevention. Mar 348–358
Goldstein BI see Sala R
Goldstein TR see Sala R
Golks D see Lambert M
Golshan S see Zisook S
Gonzalez CH see Prazeres AM
González-Pinto A see Rapado-Castro M; Tohen M
Goodman DW see Weiss MD
Goodman WK see Meyer RE
Goodness T see Freeman MP
Goodwin FK see Ghaemi SN; Meyer RE
Gorwood PAPM see Corruble E
Goulding SM see Compton MT
Gracious BL, Cook SR, Meyer AE, Chirieac MC, Malhi N, Fischetti AT, Finucane TL, Ma Y. Prevalence of overweight and obesity in adolescents with severe mental illness: a cross-sectional chart review. July 949–954
Graell M see Rapado-Castro M
Grandi S see Fava GA
Grant BF see Alegría AA; Blanco C; Oquendo MA
Grant JE see Blanco C
Greden JF see Meyer RE
Green CA see Winhusen TM
Green KT, Calhoun PS, Dennis MF, Mid-Atlantic Mental Illness Research, Education and Clinical Center Workgroup, Beckham JC. Exploration of the resilience construct in posttraumatic stress disorder severity and functional correlates in military combat veterans who have served since September 11, 2001. July 823–830
Greene CJ see Morland LA
Greene MB, Frank J, Kremer S, Bursztejn C, Foucher J. Manic psychosis and auditory hallucinations following traumatic brain injury in a 13-year-old boy [letter]. Apr 506–507
Greenfield SF see Shinn AK
Greil W see Stübner S
Griez EJL see Cosci F
Grilo CM, Stout RL, Markowitz JC, Sanislow CA, Ansell EB, Skodol AE, Bender DS, Pinto A, Shea MT, Yen S, Gunderson JG, Morey LC, Hopwood CJ, McGlashan TH. Personality disorders predict relapse after remission from an episode of major depressive disorder: a 6-year prospective study. Dec 1629–1635
Grilo CM see White MA
Grobbee DE see Laan W
Grohmann R see Stübner S
Gruber SA see Hooley JM
Grunze H see Post RM
Gueorguieva RV see Woods SW
Guerdjikova AI see McElroy SL
Guevara-Ramos LM. Review of Fontes LA: *Interviewing Clients Across Cultures: A Practitioner's Guide*. Feb 213
Guico-Pabia CJ see Kornstein SG; Lobello KW
Guillaumot J see Hooley JM
Gunderson JG see Grilo CM
Gureje O see Borges G
Gustavsson JP see Jokinen J
Gutheil TG. Review of Slovenko R: *Psychiatry in Law/Law in Psychiatry, 2nd ed.* Dec 1704
Ha W see Sala R
Haavik J see Halmøy A
Hajak G see Kasper S
Hale WW III, Klimstra TA, Meeus WHJ. Is the generalized anxiety disorder symptom of worry just another form of neuroticism? a 5-year longitudinal study of adolescents from the general population. July 942–948

Hall AJ see Toblin RL
Halleland H see Halmøy A
Halmi KA. Review of Mitchell JE, Devlin MJ, de Zwaan M, Crow SJ, Peterson CB: *Binge-Eating Disorder: Clinical Foundations and Treatment.* Apr 509
Halmøy A, Halleland H, Dramsdahl M, Bergsholm P, Fasmer OB, Haavik J. Bipolar symptoms in adult attention-deficit/hyperactivity disorder: a cross-sectional study of 510 clinically diagnosed patients and 417 population-based controls. Jan 48–57
Hammerness P see Wilens TE
Hanusa BH see Bogen DL
Haro JM see Rosa AR
Harral EM see Pavuluri MN
Harrigan SM see Henry LP
Harris MG see Henry LP
Harris TB see Vogelzangs N
Harsh JR see Krystal AD
Harvard/VA PTSD Twin Study Investigators see Gilbertson MW
Hasin DS see Alegría AA; Blanco C; Oquendo MA
Hauff E see Berg AO
Haukka J see Melartin TK
Hauth I see Wiethoff K
Hawkins KA see Woods SW
Hay A see Perlis RH
He Q see Morland LA
Health ABC Study see Vogelzangs N
Heijnen CJ see Laan W
Henkel V see Seemüller F
Hennen J see Ghaemi SN
Henry LP, Amminger GP, Harris MG, Yuen HP, Harrigan SM, Prosser AL, Schwartz OS, Farrelly SE, Herrman H, Jackson HJ, McGorry PD. The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission. June 716–728
Henry R see Jin H
Henter ID see DiazGranados N; Salvadore G
Herrman H see Henry LP
Herrmann N see Rapoport MJ
Heuser I see Seemüller F; Zeugmann S
Hewer W see Bundy BD
Hides L see Baker AL
Higuchi T. Major depressive disorder treatment guidelines in Japan. Suppl E1, e05
Higuchi T see Nutt DJ
Hill M see Goff DC
Hirschfeld RMA, Bowden CL, Vigna NV, Wozniak P, Collins M. Randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania. Apr 426–432
Ho CKW see Lam SP
Hodgkins PS see Weiss MD
Hoek HW see Slotema CW
Hollander E, Stein DJ, Fineberg NA, Marteau F, Legault M. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse. June 784–792
Hollinde D see Wiethoff K
Holsboer F see Seemüller F
Holt RIG, Pendlebury J, Wildgust HJ, Bushe CJ. Intentional weight loss in overweight and obese patients with severe mental illness: 8-year experience of a behavioral treatment program. June 800–805
Honer WG see Procyshyn RM; Torres IJ
Hoogendijk WJG see Kasper S; van Mill JG
Hooley JM, Gruber SA, Parker HA, Guillaumot J, Rogowska J, Yurgelun-Todd DA. Neural processing of emotional overinvolvement in borderline personality disorder. Aug 1017–1024
Hoop JG, Lapid MI, Paulson RM, Roberts LW. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 "early adopting" departments of psychiatry. June 745–753
Hopwood CJ see Grilo CM
Horvath A see Stübner S
Horwitz SM, Demeter CA, Pagano ME, Youngstrom EA, Fristad MA, Arnold LE, Birmaher B, Gill MK, Axelson D, Kowatch RA, Frazier TW, Findling RL. Longitudinal Assessment of Manic Symptoms (LAMS) study: background, design, and initial screening results. Nov 1511–1517
Horwitz SM see Findling RL
Hou W-H, Chiang P-T, Hsu T-Y, Chiu S-Y, Yen Y-C. Treatment effects of massage therapy in depressed people: a meta-analysis. July 894–901
Hou Z see Yuan Y
Houston JP, Ketter TA, Tohen M, Case MG, Degenhardt EK, Jamal HH. Reply to de Leon J: Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied [letter]. July 958–959
Houston JP see Perlis RH
Hower H see Sala R
Hsu C-W see Lin C-H
Hsu T-Y see Hou W-H
Hu C see Borges G
Huber CG see Lambert M
Hunt J see Sala R
Husain MM see Smith GE
Hwang I see Borges G
Hwang T-J, Ni H-C, Chen H-C, Lin Y-T, Liao S-C. Risk predictors for hypnosedative-related complex sleep behaviors: a retrospective, cross-sectional pilot study. Oct 1331–1335
Hwang T-J see Lin C-C
Hwu H-G see Chan H-Y
Ibrahim LA see DiazGranados N
Ice KS see Bowden CL
Ichimiya T see Saijo T
Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden H. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. Jan 14–25
Isometsä ET see Melartin TK
Ito H see Arakawa R; Saijo T
Iyengar S see Sala R
Jabben N, Arts B, van Os J, Krabbendam L. Neurocognitive functioning as intermediary phenotype and predictor of psychosocial functioning across the psychosis continuum: studies in schizophrenia and bipolar disorder. June 764–774
Jackson HJ see Henry LP
Jamal HH see Houston JP
Janavs J see Sheehan DV
Janssen J see Koolschijn PCMP
Jefferson JW. Clinician's guide to monitoring kidney function in lithium-treated patients. Sept 1153–1157
Jefferson L see McElroy SL
Jensen VD see Baandrup L
Jerrell JM, McIntyre RS, Tripathi A. Cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. Nov 1518–1525
Jeste D see Jin H
Jeste DV see Meyers BS
Jiang Q see Kornstein SG; Lobello KW
Jiang T see Yuan Y
Jiménez-Arriero MA see Vieta E
Jin H, Meyer J, Mudaliar S, Henry R, Khandrika S, Glorioso DK, Kraemer H, Jeste D. Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patients. Oct 1273–1278
Johnson JL see Procyshyn RM
Johnson ML see Mehta S
Jokinen J, Forslund K, Ahnemark E, Gustavsson JP, Nordström P, Åsberg M. Karolinska Interpersonal Violence Scale predicts suicide in suicide attempters. Aug 1025–1032
Joshi KG see Molina SM
Jylhä PJ see Melartin TK
Kahn RS see Boter H; Koolschijn PCMP; Laan W
Kalarchian MA see White MA
Kalavar JS see Kunik ME
Kanba S see Nutt DJ
Kane JM. Strategies for making an accurate differential diagnosis of schizoaffective disorder. Suppl 2, 4–7

Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. Sept 1115–1124
Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RSE. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. Nov 1475–1481
Kang JI see Koh KB
Kang X, Simpson GM. Clozapine: more side effects but still the best antipsychotic [commentary]. Aug 982–984
Kaplan JA see Toblin RL
Kapur S see Sparshatt A
Karagianis JL see Marder SR
Karajgi B see Schwarcz G
Karam EG see Borges G
Karamustafalioğlu O. Major depressive disorder, mental health care, and the use of guidelines in the Middle East. Suppl E1, e07
Karamustafalioğlu O see Nutt DJ
Kasckow JW see Zisook S
Kasper S, Hajak G, Wulff K, Hoogendijk WJG, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. Feb 109–120
Kauer-Sant'Anna M see Torres IJ
Keane TM see Gilbertson MW
Keck PE Jr see McElroy SL; Post RM
Keefe RSE see Kane JM
Keeshin BR see Strawn JR
Keller MB see Sala R
Kelley ME see Ghaemi SN
Kellner CH see Smith GE
Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim J-C, Warren KR, Conley RR. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. Mar 304–311
Kemp DE, Calabrese JR, Tran Q-V, Pikalov A, Eudicone JM, Baker RA. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Sept 1138–1144
Kennedy SM see Findling RL
Kessler RC see Borges G
Ketter TA. Diagnostic features, prevalence, and impact of bipolar disorder. June e14
Ketter TA. Nosology, diagnostic challenges, and unmet needs in bipolar disorder. Oct e27
Ketter TA see Calabrese JR; Houston JP
Khan A see Stein MB
Khandrika S see Jin H
Kiermeir J see Wiethoff K
King DA see Boyle LL
Kiss A see Rapoport MJ; Sinyor M
Kivimäki M see Virtanen M
Klimstra TA see Hale WW III
Klumpers F see Koolschijn PCMP
Knapp RG see Smith GE
Knegtering R see Dlabač-de Lange JJ
Knuts IJE see Cosci F
Ko RWY see Procyshyn RM
Koeter MWJ see ten Doesschate MC
Koh KB, Kang JI, Lee JD, Lee Y. Shared neural activity in panic disorder and undifferentiated somatoform disorder compared with healthy controls. Dec 1576–1581
Kolassa I-T, Ertl V, Eckart C, Glöckner F, Kolassa S, Papassotiropoulos A, de Quervain DJ-F, Elbert T. Association study of trauma load and *SLC6A4* promoter polymorphism in posttraumatic stress disorder: evidence from survivors of the Rwandan genocide. May 543–547
Kolassa S see Kolassa I-T
Koolschijn PCMP, van Haren NEM, Cahn W, Schnack HG, Janssen J, Klumpers F, Pol HEH, Kahn RS. Hippocampal volume change in schizophrenia. June 737–744
Kopparthi S see Wieck A
Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. Aug 1088–1096
Kosik-Gonzalez C see Canuso CM
Koszewska I see Rybakowski JK
Kotzalidis GD see Manfredi G
Koukopoulos AE see Manfredi G
Kovess-Masfety V see Borges G
Kowatch RA see Findling RL; Horwitz SM
Krabbendam L see Jabben N
Kraemer H see Jin H
Kramer M. Review of Reite M, Weissberg M, Ruddy J: *Clinical Manual for Evaluation and Treatment of Sleep Disorders.* Aug 1104
Kremer S see Greene MB
Kritchevsky SB see Vogelzangs N
Kron S see Levkovitz Y
Kronmüller K see Seemüller F
Kronmüller K-T see Wiethoff K
Krystal AD, Harsh JR, Yang RR, Rippon GA, Lankford DA. Double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. Jan 32–40
Kuk AYC, Li J, Rush AJ. Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care. Nov 1502–1508
Kulisevsky J see Dávila G
Kunik ME, Snow AL, Davila JA, Steele AB, Balasubramanyam V, Doody RS, Schulz PE, Kalavar JS, Morgan RO. Causes of aggressive behavior in patients with dementia. Sept 1145–1152
Kunz M see de Lucena D
Kuo C-J, Tsai S-Y, Liao Y-T, Lee W-C, Sung X-W, Chen C-C. Psychiatric discharge against medical advice is a risk factor for suicide but not for other causes of death. June 808–809
Kuperman S see Calarge CA
Kupfer DJ see Leboyer M
Kupka RW see Post RM
Laan W, Grobbee DE, Selten J-P, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. May 520–527
Labbate LA. Review of Balon R, Segraves R (eds): *Clinical Manual of Sexual Disorders.* Sept 1251
Lackamp JM. Review of Balon R (ed): *Sexual Dysfunction: The Brain-Body Connection.* Jan 94
Lafay P see Ingenhoven T
Lai C-H. Aripiprazole-induced gray matter growth in a patient with major depressive disorder with panic disorder [letter]. Mar 360
Lai M-S see Chan H-Y
Lake J see Freeman MP
Lam C see Sansone RA
Lam RW see Torres IJ
Lam SP, Zhang J, Tsoh J, Li SX, Ho CKW, Mok V, Chan AYY, Wing YK. REM sleep behavior disorder in psychiatric populations [letter]. Aug 1101–1103
Lam SP see Li SX; Wing YK
Lambert M, Bock T, Schöttle D, Golks D, Meister K, Rietschel L, Bussopulos A, Frieling M, Schödlbauer M, Burlon M, Huber CG, Ohm G, Pakrasi M, Chirazi-Stark MS, Naber D, Schimmelmann BG. Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS Trial). Oct 1313–1323

Lamers F, de Jonge P, Nolen WA, Smit JH, Zitman FG, Beekman ATF, Penninx BWJH. Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA). Dec 1582–1589
Lanctôt KL see Rapoport MJ; Sinyor M
Landgraf JM see Weiss MD
Lane H-Y see Lin C-H
Lankford DA see Krystal AD
Lanosa M see Ehret M
Lanouette NM see Zisook S
Lapid MI see Hoop JG
Lasko NB see Gilbertson MW
Laughren TP. What's next after 50 years of psychiatric drug development: an FDA perspective. Sept 1196–1204
Laux G see Seemüller F; Wiethoff K
Lazanio S see Manfredi G
Lebowitz B see Zisook S
Leboyer M, Kupfer DJ. Bipolar disorder: new perspectives in health care and prevention. Dec 1689–1695
Lee JD see Koh KB
Lee S see Borges G
Lee W-C see Kuo C-J
Lee Y see Koh KB
Le Gall D see Richard-Devantoy S
Legault M see Hollander E
Leigh H. Review of Seeley KM: *Therapy After Terror: 9/11, Psychotherapists, and Mental Health.* Apr 509
Leimberger JD see Winhusen TM
Lerner V see Ritsner MS
Leverich GS see Post RM
Levinson D see Borges G
Levitt AJ see Sinyor M
Levkovitch-Verbin H see Levkovitz Y
Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S. Double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. Feb 138–149
Levy B, Weiss RD. Neurocognitive impairment and psychosis in bipolar I disorder during early remission from an acute episode of mood disturbance. Feb 201–206
Lewis DF see Winhusen TM
Li J see Kuk AYC
Li SX, Lam SP, Yu MWM, Zhang J, Wing YK. Nocturnal sleep disturbances as a predictor of suicide attempts among psychiatric outpatients: a clinical, epidemiologic, prospective study. Nov 1440–1446
Li SX see Lam SP; Wing YK
Li Y-C see Lin C-C
Liao F see Sala R
Liao S-C see Hwang T-J
Liao Y-T see Kuo C-J
Liebowitz MR see Stein MB
Lien L see Berg AO
Lin C-C, Bai Y-M, Chen J-Y, Hwang T-J, Chen T-T, Chiu H-W, Li Y-C. Easy and low-cost identification of metabolic syndrome in patients treated with second-generation antipsychotics: artificial neural network and logistic regression models. Mar 225–234
Lin C-H, Hsu C-W, Lin C-H, Lane H-Y. Case of mirtazapine-associated hair loss [letter]. Oct 1400–1401
Lin C-H see Lin C-H
Lin D see Tohen M
Lin Y-T see Hwang T-J
Lindenmayer J-P see Canuso CM
Lindhardt A see Baandrup L
Liptzin B. Review of Parker G (ed): *Bipolar II Disorder: Modelling, Measuring and Managing.* Feb 213–214
Liptzin B, Fischel SV. Review of Guggenheim FG: *Prime Time: Maximizing the Therapeutic Experience: A Primer for Psychiatric Clinicians.* Aug 1104–1105
Liu DS see Winhusen TM
Liu F see Kelly DL
Liu S-M see Alegría AA; Blanco C; Oquendo MA
Liu W see Yuan Y
Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva A, Ninan PT. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. Nov 1482–1487
Logan JE see Toblin RL
Long ME see Richardson JD
Lönn SL see Bech P
Lopera-Vásquez J see López-Jaramillo C
López-Jaramillo C, Lopera-Vásquez J, Ospina-Duque J, García J, Gallo A, Cortez V, Palacio C, Torrent C, Martínez-Arán A, Vieta E. Lithium treatment effects on the neuropsychological functioning of patients with bipolar I disorder. Aug 1055–1060
Love RC see Kelly DL
Lublin H see Baandrup L
Lubman DI see Baker AL
Luckenbaugh DA see DiazGranados N; Post RM
Lu M-K see Wu C-C
Lydiard RB see Stein MB
Lyness JM see Boyle LL
Ma Y see Gracious BL
Maayan R see Ritsner MS
MacCabe JH see Crews MPK
Machado-Vieira R see DiazGranados N; Salvadore G
Madowitz J see Zisook S
Maeda J see Arakawa R
Malhi N see Gracious BL
Maltsberger JT see Weinberg I
Mancebo MC see Eisen JL
Mancini C see Van Ameringen M
Mandelli L see Serretti A
Manfredi G, Kotzalidis GD, Lazanio S, Savoja V, Talamo A, Koukopoulos AE, Sani G, Trevisi M, Tatarelli R, Girardi P. Command hallucinations with self-stabbing associated with zolpidem overdose [letter]. Jan 92–93
Mangelli L see Fava GA
Manji HK see Salvadore G
Mann JJ see Meyer RE
Manning JS. What alternatives to first-line therapy for depression are effective? Suppl 1, 10–15
Marcus MD see White MA
Marcus SC see Olfson M
Marcus SM see Rodriguez CI
Marder SR. Review of Meyer JM, Nasrallah HA (eds): *Medical Illness and Schizophrenia.* Dec 1702–1703
Marder SR, Sorsaburu S, Dunayevich E, Karagianis JL, Dawe IC, Falk DM, Dellva MA, Carlson JL, Cavazzoni PA, Baker RW. Case reports of post-marketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. Apr 433–441
Markowitz JC see Blanco C; Grilo CM
Marmot M see Singh-Manoux A
Marquardt L see Zink M
Marrocos RP see Prazeres AM
Marsh L see Findling RL
Marteau F see Hollander E
Martelon M see Wilens TE
Martens BE see McElroy SL
Martens EJ, Mols F, Burg MM, Denollet J. Type D personality predicts clinical events after myocardial infarction, above and beyond disease severity and depression. June 778–783
Martínez-Arán A see López-Jaramillo C
Masheb RM see White MA
McCullagh S see Rapoport MJ
McDougle CJ see Forray A
McElhiney MC see Rabkin JG
McElroy SL, Martens BE, Creech RS, Welge JA, Jefferson L, Guerdjikova AI, Keck PE Jr. Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania. May 557–565
McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH, EMBOLDEN II (Trial D1447C00134) Investigators. Double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Feb 163–174

McElroy SL see Post RM; Young AH
McFarlane AC see Gilbertson MW
McGlashan TH see Grilo CM
McGlinchey JB see Zimmerman M
McGorry PD see Gleeson JFM; Henry LP
McGrath PJ see Rabkin JG
McIntyre RS. When should you move beyond first-line therapy for depression? Suppl 1, 16–20
McIntyre RS see Jerrell JM
McIsaac SA see Procyshyn RM
McMahon RP see Kelly DL
McMillan KA, Enns MW, Asmundson GJG, Sareen J. Association between income and distress, mental disorders, and suicidal ideation and attempts: findings from the Collaborative Psychiatric Epidemiology Surveys. Sept 1168–1175
McNeil JJ see Ronaldson KJ
Medina-Mora ME see Borges G
Meeus WHJ see Hale WW III
Mehta S, Johnson ML, Chen H, Aparasu RR. Risk of cerebrovascular adverse events in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. June 689–698
Meister K see Lambert M
Melartin TK, Haukka J, Rytsälä HJ, Jylhä PJ, Isometsä ET. Categorical and dimensional stability of comorbid personality disorder symptoms in *DSM-IV* major depressive disorder: a prospective study. Mar 287–295
Melchior M see Singh-Manoux A
Meleiro A see Boggio PS
Melle I see Berg AO
Meltzer HY see Meyer RE
Mendlovich S see Levkovitz Y
Mendlowicz MV see Prazeres AM
Merideth C see McElroy SL
Mersch PPA see van Apeldoorn FJ
Mesu C see Richard-Devantoy S
Meyer AE see Gracious BL
Meyer J see Jin H
Meyer RE, Salzman C, Youngstrom EA, Clayton PJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand S-LT, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley CM Jr, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV. Suicidality and risk of suicide—definition, drug safety concerns, and a necessary target for drug development: a brief report. Aug 1040–1046
Meyer RE, Salzman C, Youngstrom EA, Clayton PJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand S-LT, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley CM Jr, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV. Suicidality and risk of suicide—definition, drug safety concerns, and a necessary target for drug development: a consensus statement. Aug e100
Meyers BS, Jeste DV. Geriatric psychopharmacology: evolution of a discipline. Nov 1416–1424
Mid-Atlantic Mental Illness Research, Education and Clinical Center Workgroup see Green KT
Miguel EC see Prazeres AM
Miklowitz DJ see Perlis RH
Miller MN. Review of Zerbe KJ: *Integrated Treatment of Eating Disorders: Beyond the Body Betrayed.* Mar 364
Milo KM see Sheehan DV
Mischoulon D see Fava M; Freeman MP
Mitchell RA see Rapoport MJ
Mohamed S see Zisook S
Mok V see Lam SP
Molina SM, Joshi KG. Case of zaleplon-induced amnestic sleep-related eating disorder [letter]. Feb 210–211
Möller H-J see Seemüller F; Stübner S; Wiethoff K
Mols F see Martens EJ
Money R see Woods SW
Montejo AL see Kasper S
Monuteaux MC see Surman CBH
Morenz B. Review of Eckenwiler LA, Cohn FG (eds): *The Ethics of Bioethics: Mapping the Moral Landscape.* Feb 214–215
Morey LC see Grilo CM
Morgan RO see Kunik ME
Morgenstern H see Woods SW
Mori N see Suda S
Morland LA, Greene CJ, Rosen CS, Foy D, Reilly P, Shore J, He Q, Frueh BC. Telemedicine for anger management therapy in a rural population of combat veterans with posttraumatic stress disorder: a randomized noninferiority trial. July 855–863
Mortensen PB see Baandrup L
Mościcki EK, West JC, Rae DS, Rubio-Stipec M, Wilk JE, Regier DA. Suicidality is associated with medication access problems in publicly insured psychiatric patients. Dec 1657–1663
Moses-Kolko E see Bogen DL
Moss SV see Citrome L
Mudaliar S see Jin H
Mueller M see Smith GE
Müller-Oerlinghausen B see Stübner S
Musgnung JJ see Kornstein SG
Muszynski IL see West JC
Naber D see Lambert M
Nagesh KS see Andrade C
Nelson SH. Review of Tseng W-S, Streltzer J: *Cultural Competence in Health Care: A Guide for Professionals.* May 657
Nestoriuc Y see Sakai R
Newman AB see Vogelzangs N
Newman B see Gleeson JFM
Nguyen VT see Cizza G
Ni H-C see Hwang T-J
Nichols AI see Lobello KW
Nierenberg AA see Perlis RH
Ninan PT see Lobello KW
Nock MK see Borges G
Nolen WA see Lamers F; Post RM; van Zaane J
Nolido NV see Sakai R
Nordenhem A see McElroy SL
Nordentoft M see Baandrup L
Nordström P see Jokinen J
Normand S-LT see Meyer RE
Nunes EV see Alegría AA; Brooks AC
Nutt DJ. Rationale for, barriers to, and appropriate medication for the long-term treatment of depression. Suppl E1, e02
Nutt DJ, Davidson JRT, Gelenberg AJ, Higuchi T, Kanba S, Karamustafalioğlu O, Papakostas GI, Sakamoto K, Terao T, Zhang M. International Consensus Statement on Major Depressive Disorder. Suppl E1, e08
Oakman J see Van Ameringen M
Obermeier M see Seemüller F
O'Brien CP see Brooks AC
O'Connor MK see Smith GE
O'Grady KE see Garnier LM
Ohm G see Lambert M
Oksanen T see Virtanen M
Okubo Y see Arakawa R; Saijo T
Okuda M see Blanco C
Okumura M see Arakawa R; Saijo T
Olausson B see McElroy SL; Young AH
Olfson M, Marcus SC, Doshi JA. Continuity of care after inpatient discharge of patients with schizophrenia in the Medicaid program: a retrospective longitudinal cohort analysis. July 831–838
Oliveira MO see Boggio PS
Oquendo MA, Currier D, Liu S-M, Hasin DS, Grant BF, Blanco C. Increased risk for suicidal behavior in comorbid bipolar disorder and alcohol use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). July 902–909
Oquendo MA see Meyer RE
Orenstein H, Raskind MA. Dosing by side effect threshold: two cases of panic disorder responsive to low-dose venlafaxine [letter]. Jan 89–91
Orlando ME see Eisen JL
Ormel J see Borges G
Ospina-Duque J see López-Jaramillo C
Ostacher MJ see Perlis RH
Ostacher MM see Ghaemi SN

Overø KF see Bech P
Padwa H. Review of Wallace ER, Gach J (eds): *History of Psychiatry and Medical Psychology: With an Epilogue on Psychiatry and the Mind-Body Relation.* May 658–659
Pagano ME see Horwitz SM
Pakrasi M see Lambert M
Palacio C see López-Jaramillo C
Papakostas GI. Efficacy, tolerability, and safety of contemporary antidepressants. Suppl E1, e03
Papakostas GI see Freeman MP; Nutt DJ
Papassotiropoulos A see Kolassa I-T
Parellada M see Rapado-Castro M
Parker HA see Hooley JM
Pascual-Leone A see Boggio PS
Passarotti AM see Pavuluri MN
Passchier J see Ingenhoven T
Patel MX see Sparshatt A
Patel SR, Simpson HB. Patient preferences for obsessive-compulsive disorder treatment. Nov 1434–1439
Patel T see Brewin CR
Patkar AA see Kane JM
Patroneva A see Lobello KW
Patterson B see Van Ameringen M
Paul J see Lobello KW
Paulozzi LJ see Toblin RL
Paulson RM see Hoop JG
Paulsson B see McElroy SL; Young AH
Pavuluri MN, Passarotti AM, Harral EM, Sweeney JA. Enhanced prefrontal function with pharmacotherapy on a response inhibition task in adolescent bipolar disorder. Nov 1526–1534
Payá B see Rapado-Castro M
Pedlar D see Richardson JD
Peele R, Benjelloun H. Review of Gunderson JG, Links PS: *Borderline Personality Disorder: A Clinical Guide, 2nd ed.* Jan 95
Pelham WE see Waxmonsky JG
Pendlebury J see Holt RIG
Penninx BWJH see Lamers F; van Mill JG; van Reedt Dortland AKB; Vogelzangs N
Pentti J see Virtanen M
Perlis RH, Adams DH, Fijal B, Sutton VK, Farmen M, Breier A, Houston JP. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. May 599–605
Perlis RH, Ostacher MJ, Miklowitz DJ, Hay A, Nierenberg AA, Thase ME, Sachs GS. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. Mar 296–303
Perlis RH, Ostacher MJ, Miklowitz DJ, Smoller JW, Dennehy EB, Cowperthwait C, Nierenberg AA, Thase ME, Sachs GS. Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report. Feb 194–200
Petrides G see Smith GE
Petry NM see Blanco C
Petty CR see Surman CBH
Pfaffenseller B see de Lucena D
Pfeffer CR. Review of Hudziak JJ (ed): *Developmental Psychopathology and Wellness: Genetic and Environmental Influences.* June 811–812
Pfuhlmann B see Fischer M
Philips N see Young AH
Picarel-Blanchot F see Kasper S
Pies R see Zisook S
Pijl H see Vidarsdottir S
Pikalov A see Kemp DE
Pinto A see Eisen JL; Grilo CM
Pipili C see Cholongitas E
Pitman RK see Gilbertson MW
Pittman B see Forray A
Pizzarello S see Post RM
Podawiltz A, Culpepper L. Family members of Hispanic military veterans: the risk of major depressive disorder. July e16
Podawiltz A, Culpepper L. Medical therapy for major depressive disorder in Latinos. Apr e08
Podawiltz A, Culpepper L. Psychotherapy for major depressive disorder in Latinos. May e11
Podawiltz A, Culpepper L. Treatment-resistant depression in Hispanic patients. June e12
Pol HEH see Koolschijn PCMP
Polak T see Fischer M
Pollack MH see Stein MB
Porcelli P see Fava GA
Porsteinsson AP see Boyle LL
Posada-Villa J see Borges G
Posner K see Meyer RE
Post A see Stahl SM
Post RM, Altshuler LL, Frye MA, Suppes T, Keck PE Jr, McElroy SL, Leverich GS, Luckenbaugh DA, Rowe M, Pizzarello S, Kupka RW, Grunze H, Nolen WA. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. Sept 1176–1186
Post RM, Leverich GS, Kupka RW, Keck PE Jr, McElroy SL, Altshuler LL, Frye MA, Luckenbaugh DA, Rowe M, Grunze H, Suppes T, Nolen WA. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. July 864–872
POWER Study Group see Cizza G
Prazeres AM, Fontenelle LF, Mendlowicz MV, de Mathis MA, Ferrão YA, de Brito NFC, Diniz JB, Gonzalez CH, Quarantini LC, Marrocos RP, Miguel EC. Olfactory reference syndrome as a subtype of body dysmorphic disorder [letter]. Jan 87–89
Preskorn SH see Lobello KW
Procyshyn RM, Honer WG, Wu TKY, Ko RWY, McIsaac SA, Young AH, Johnson JL, Barr AM. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. May 566–573
Prosser AL see Henry LP
Putnam FW see Strawn JR
Puzynski S see Rybakowski JK
Quante A see Zeugmann S
Quarantini LC see Prazeres AM
Quera-Salva MA see Kasper S
Quiroz JA see Salvadore G
Rabins PV. Review of Dimsdale JE, Xin Y, Kleinman A, Patel V, Narrow WE, Sirovatka PJ, Regier DA (eds): *Somatic Presentations of Mental Disorders: Refining the Research Agenda for DSM-V.* Dec 1702
Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ. Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. June 707–715
Rabkin R see Rabkin JG
Raby WM see Brooks AC
Racy JC. Review of Mathews DJH, Bok H, Rabins PV (eds): *Personal Identity and Fractured Selves: Perspectives From Philosophy, Ethics, and Neuroscience.* Sept 1250–1251
Rae DS see Mościcki EK; West JC
Rafanelli C see Fava GA
Ragheb M see Zimmerman M
Raj YP. Gambling on acamprosate: a case report [letter]. Sept 1245–1246
Randall ML. Review of Higgins ST, Silverman K, Heil SH (eds): *Contingency Management in Substance Abuse Treatment.* Apr 509–510
Rao S see Zisook S
Rapado-Castro M, Soutullo C, Fraguas D, Arango C, Payá B, Castro-Fornieles J, González-Pinto A, Parellada M, Graell M, Baeza I, Bombin I. Predominance of symptoms over time in early-onset psychosis: a principal component factor analysis of the Positive and Negative Syndrome Scale. Mar 327–337
Rapoport MJ, Mitchell RA, McCullagh S, Herrmann N, Chan F, Kiss A, Feinstein A, Lanctôt KL. Randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury. Sept 1125–1130
Raskind MA see Orenstein H
Rasmussen KG Jr see Smith GE
Rasmussen SA see Eisen JL
Ravindran LN, Stein MB. Pharmacologic treatment of anxiety disorders: a review of progress. July 839–854
Ravindran LN see Stein MB

Reddy S see Kornstein SG
Reed C see Rosa AR; Tohen M
Regan WM. Review of McCarron RM, Xiong GL, Bourgeois JA (eds): *Lippincott's Primary Care Psychiatry.* Nov 1557
Regier DA see Mościcki EK; West JC
Reif A see Fischer M
Reilly P see Morland LA
Reilly T see Chavez B
Reiman EM. Cognizance of cognition in older primary care patients with depression and restraining restraint and agitation in nursing home residents with dementia. Jan 73
Rejas J see Bobes J
Revicki DA see Meyer RE
Reynolds CF III see Zisook S
Reynolds JC see Cizza G
Richard-Devantoy S, Gallarda T, Annweiler C, Dorey J-M, Mesu C, Garré J-B, Le Gall D, Beauchet O. Homicide and dementia in older adults: the key role of dysexecutive function [letter]. Oct 1402–1403
Richardson JD, Long ME, Pedlar D, Elhai JD. Posttraumatic stress disorder and health-related quality of life in pension-seeking Canadian World War II and Korean War veterans [letter]. Aug 1099–1101
Richelson E. New antipsychotic drugs: how do their receptor-binding profiles compare? [ASCP Corner] Sept 1243–1244
Riedel M see Seemüller F
Rietschel L see Lambert M
Rinne T see Ingenhoven T
Rippon GA see Krystal AD
Ritchie K see Scali J
Ritsner MS, Gibel A, Shleifer T, Boguslavsky I, Zayed A, Maayan R, Weizman A, Lerner V. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. Oct 1351–1362
Riwkes S see Levkovitz Y
Roberts LW see Hoop JG
Roberts MW. Review of Turk J, Graham P, Verhulst FC: *Child and Adolescent Psychiatry: A Developmental Approach.* Apr 508
Rocha M see Boggio PS
Rodriguez A see Vieta E
Rodriguez CI, Bender J Jr, Marcus SM, Snape M, Rynn M, Simpson HB. Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial [letter]. Sept 1247–1249
Roelfsema F see Vidarsdottir S
Rogers JE see Sheehan DV
Rogowska J see Hooley JM
Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, Elsik M, McNeil JJ. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. Aug 976–981
Ronningstam E see Weinberg I
Rosa AR, Cruz N, Franco C, Haro JM, Bertsch J, Reed C, Aarre TF, Sanchez-Moreno J, Vieta E. Why do clinicians maintain antidepressants in some patients with acute mania? hints from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM), a large naturalistic study. Aug 1000–1006
Rosen CS see Morland LA
Rotella B see Waxmonsky JG
Roth T, Benca RM, Erman M. Introduction to the clinical correlates of disrupted slow-wave sleep. Apr e09
Rowe M see Post RM
Rowles BM see Findling RL
Rubio-Stipec M see Mościcki EK; West JC
Ruggero CJ see Zimmerman M
Ruiz P. Review of Fernando S, Keating F (eds): *Mental Health in a Multi-Ethnic Society.* Nov 1556
Rummans TA see Smith GE
Rush AJ see Kuk AYC
Rüther E see Stübner S
Ryan J see Scali J
Ryan L see Waxmonsky JG
Ryan N see Findling RL
Ryan ND see Meyer RE; Sala R
Rybakowski JK, Koszewska I, Puzynski S. Anticholinergic mechanisms: a forgotten cause of the switch process in bipolar disorder [letter with reply]. Dec 1698–1699
Rybakowski JK see Kasper S
Rydén EM see Bejerot S
Rynn M see Rodriguez CI
Rytsälä HJ see Melartin TK
Sabia S see Singh-Manoux A
Sachs GS, Goodwin FK, Baldessarini RJ. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. Apr 372–380
Sachs GS see Ghaemi SN; Perlis RH
Sagar R see Borges G
Saijo T, Takano A, Suhara T, Arakawa R, Okumura M, Ichimiya T, Ito H, Okubo Y. Electroconvulsive therapy decreases dopamine D_2 receptor binding in the anterior cingulate in patients with depression: a controlled study using positron emission tomography with radioligand [^{11}C]FLB 457. June 793–799
Sakai R, Nestoriuc Y, Nolido NV, Barsky AJ. Prevalence of personality disorders in hypochondriasis. Jan 41–47
Sakamoto K see Nutt DJ
Saksa JR see Woods SW
Saia R, Axelson DA, Castro-Fornieles J, Goldstein TR, Ha W, Liao F, Gill MK, Iyengar S, Strober MA, Goldstein BI, Yen S, Hower H, Hunt J, Ryan ND, Dickstein D, Keller MB, Birmaher B. Comorbid anxiety in children and adolescents with bipolar spectrum disorders: prevalence and clinical correlates. Oct 1344–1350
Salo P see Virtanen M
Salvadore G, Henter ID, Zarate CA Jr. Reply to Rybakowski JK: Anticholinergic mechanisms: a forgotten cause of the switch process in bipolar disorder [letter]. Dec 1699–1700
Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA Jr. Neurobiology of the switch process in bipolar disorder: a review. Nov 1488–1501
Salzman C. Review of Rosowsky E, Casciani JM, Arnold M (eds): *Geropsychology and Long Term Care: A Practitioner's Guide.* Nov 1556
Salzman C see Meyer RE
Sampson NA see Borges G
Sampson S see Smith GE
Sanchez-Moreno J see Rosa AR
Sandarsh S see Andrade C
Sanders KE see West JC
Sani G see Manfredi G
Sanislow CA see Grilo CM
Sansone RA, Lam C, Wiederman MW. Borderline personality disorder and reckless driving [letter]. Apr 507
Sareen J see McMillan KA
Sartorius A see Bundy BD; Zink M
Satterfield S see Vogelzangs N
Savoja V see Manfredi G
Scali J, Ryan J, Carrière I, Dartigues J-F, Tavernier B, Ritchie K, Ancelin M-L. Prospective study of hormone therapy and depression in community-dwelling elderly women: the Three City Study. Dec 1673–1679
Schaffer A see Sinyor M
Schechter M see Weinberg I
Schene AH see ten Doesschate MC
Schennach-Wolff R see Seemüller F
Schimmelmann BG see Lambert M
Schlechte JA see Calarge CA
Schnack HG see Koolschijn PCMP
Schödlbauer M see Lambert M
Schooler NR see Canuso CM
Schöttle D see Lambert M
Schruers KRJ see Cosci F
Schulz PE see Kunik ME
Schuurmans J see van Oppen P
Schwarcz G, Karajgi B. Improvement in refractory psychosis with dronabinol: four case reports [letter]. Nov 1552–1553
Schwartz JH see Bowden CL

Schwartz OS see Henry LP
Schwarzer R see Zeugmann S
Seemüller F, Möller H-J, Obermeier M, Adli M, Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, Riedel M. Do efficacy and effectiveness samples differ in antidepressant treatment outcome? an analysis of eligibility criteria in randomized controlled trials. Nov 1425–1433
Selten J-P see Laan W
Serper MR see Berman BA
Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. Oct 1259–1272
Shaffer D see Meyer RE
Shah A see Stahl SM
Shalev AY see Gilbertson MW
Sharfstein SS. Review of Gabbard GO (ed): *Textbook of Psychotherapeutic Treatments*. Sept 1250
Shea MT see Grilo CM
Shear MK see Zisook S
Sheehan DV, Sheehan KH, Shytle RD, Janavs J, Bannon Y, Rogers JE, Milo KM, Stock SL, Wilkinson B. Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). Mar 313–326
Sheehan DV see Meyer RE
Sheehan KH see Sheehan DV
Shen W-C see Wu C-C
Shi Y see Yuan Y
Shim J-C see Kelly DL
Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. May 634–648
Shleifer T see Ritsner MS
Shore J see Morland LA
Shytle RD see Sheehan DV
Simon N see Zisook S
Simon NM see Stein MB; Zisook S
Simpson GM see Kang X
Simpson HB see Blanco C; Patel SR; Rodriguez CI
SIN-DEPRES Group see Vieta E
Singh-Manoux A, Akbaraly TN, Marmot M, Melchior M, Ankri J, Sabia S, Ferrie JE. Persistent depressive symptoms and cognitive function in late midlife: the Whitehall II Study. Oct 1379–1385
Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctôt KL. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? results from pooled and meta-analyses. Mar 270–279
Skodol AE see Grilo CM
Slotema CW, Blom JD, Hoek HW, Sommer IEC. Should we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? a meta-analysis of the efficacy of rTMS in psychiatric disorders. July 873–884
Small GW. Pharmacotherapy and other treatments for elderly patients with depression. Jan e03
Smeraldi E see Kasper S
Smit JH see Lamers F; Thomaes K; van Oppen P; van Zaane J
Smith GE, Rasmussen KG Jr, Cullum CM, Felmlee-Devine MD, Petrides G, Rummans TA, Husain MM, Mueller M, Bernstein HJ, Knapp RG, O'Connor MK, Fink M, Sampson S, Bailine SH, Kellner CH, CORE Investigators. Randomized controlled trial comparing the memory effects of continuation electroconvulsive therapy versus continuation pharmacotherapy: results from the Consortium for Research in ECT (CORE) study. Feb 185–193
Smoller JW see Perlis RH
Snape M see Rodriguez CI
Snow AL see Kunik ME
Soffer Y see Ben-Ezra M
Sommer IEC see Slotema CW
Somoza EC see Winhusen TM
Sorsaburu S see Marder SR
Soutullo C see Rapado-Castro M
Sparhawk R. Antidepressants in bipolar disorder: caveats in interpreting and applying the findings of Altshuler et al [letter with reply]. Feb 211–212
Sparshatt A, Taylor D, Patel MX, Kapur S. Systematic review of aripiprazole—dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. Nov 1447–1456
Spencer TJ see Surman CBH
Spiliotacopoulos D see Gleeson JFM
Spina E see de Leon J
Stagno SJ. Review of Gutheil TG, Brodsky A: *Preventing Boundary Violations in Clinical Practice*. May 659
Stahl SM. Circuits of sexual desire in hypoactive sexual desire disorder [Brainstorms]. May 518–519
Stahl SM. Illustrating the circuits of sexual desire [Brainstorms]. Sept 1113–1114
Stahl SM. Mechanism of action of α_{2A}-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms [Brainstorms]. Mar 223–224
Stahl SM. Mechanism of action of stimulants in attention-deficit/hyperactivity disorder [Brainstorms]. Jan 12–13
Stahl SM. Serotonin-7 receptor as a novel therapeutic target [Brainstorms]. Nov 1414–1415
Stahl SM. Targeting circuits of sexual desire as a treatment strategy for hypoactive sexual desire disorder [Brainstorms]. July 821–822
Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. May 616–626
Stanley B see Meyer RE
Steele AB see Kunik ME
Stein DJ see Hollander E
Stein MB, Ravindran LN, Simon NM, Liebowitz MR, Khan A, Brawman-Mintzer O, Lydiard RB, Pollack MH. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. May 627–631
Stein MB see Ravindran LN
Stertz L see de Lucena D
St-Jacques J, Bouchard S, Bélanger C. Is virtual reality effective to motivate and raise interest in phobic children toward therapy? a clinical trial study of in vivo with in virtuo versus in vivo only treatment exposure. July 924–931
Stock SL see Sheehan DV
Stout RL see Grilo CM
Strawn JR, Keeshin BR, DelBello MP, Geracioti TD Jr, Putnam FW. Psychopharmacologic treatment of posttraumatic stress disorder in children and adolescents: a review. July 932–941
Strober MA see Sala R
Stübner S, Grohmann R, von Stralendorff I, Rüther E, Möller H-J, Müller-Oerlinghausen B, Engel RR, Horvath A, Greil W. Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. Oct 1293–1307
Su K-P see Wu C-C
Suda S, Sugihara G, Suyama R, Mori N, Takei N. Donepezil and concurrent sertraline treatment is associated with increased hippocampal volume in a patient with depression [letter]. June 806–808
Sugihara G see Suda S
Suhara T see Arakawa R; Saijo T
Sullivan MA see Brooks AC
Sullivan MC see Woods SW
Sundaresh S see Wieck A
Sung X-W see Kuo C-J
Suppes T see Post RM

Surman CBH, Monuteaux MC, Petty CR, Faraone SV, Spencer TJ, Chu NF, Biederman J. Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? comparison with adults from a large observational study. Dec 1612–1616
Sutton VK see Perlis RH
Suyama R see Suda S
Suzuki T, Takeuchi H, Watanabe K. Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine? [letter with reply] Nov 1553–1554
Sweeney JA see Pavuluri MN
Szentagotai A, David D. Efficacy of cognitive-behavioral therapy in bipolar disorder: a quantitative meta-analysis. Jan 66–72
Takahashi H see Arakawa R
Takano A see Arakawa R; Saijo T
Takano H see Arakawa R
Takei N see Suda S
Takeuchi H see Suzuki T
Talamo A see Manfredi G
Tal-Young I see Zisook S
Tatarelli R see Manfredi G
Tavernier B see Scali J
Taylor AJ see Ronaldson KJ
Taylor D see Sparshatt A
Taylor SL see Valdovinos MG
Tedeschini E see Freeman MP
ten Doesschate MC, Bockting CLH, Koeter MWJ, Schene AH, DELTA Study Group. Prediction of recurrence in recurrent depression: a 5.5-year prospective study. Aug 984–991
Terao T see Nutt DJ
Terho K see Virtanen M
Testad I, Ballard C, Brønnick K, Aarsland D. Effect of staff training on agitation and use of restraint in nursing home residents with dementia: a single-blind, randomized controlled trial. Jan 80–86
Thase ME. Role of neurobiologic processes in treating depression. Oct e28
Thase ME see Gelenberg AJ; Perlis RH; Tohen M
The GKH, Bleijenberg G, Buitelaar JK, van der Meer JWM. Effect of ondansetron, a 5-HT_3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial. May 528–533
Thienhaus OJ. Review of Stahl SM: *Essential Psychopharmacology: The Prescriber's Guide: Antidepressants.* Nov 1556–1557
Thomaes K, Dorrepaal E, Draijer N, de Ruiter MB, van Balkom AJ, Smit JH, Veltman DJ. Reduced anterior cingulate and orbitofrontal volumes in child abuse–related complex PTSD. Dec 1636–1644
Tiller JM see Calabrese JR; Kane JM
Timmerman ME see van Apeldoorn FJ
Tinsley JA. Review of Grant JE: *Impulse Control Disorders: A Clinician's Guide to Understanding and Treating Behavioral Addictions.* Mar 363
Toba C see Zimmerman M
Toblin RL, Paulozzi LJ, Logan JE, Hall AJ, Kaplan JA. Mental illness and psychotropic drug use among prescription drug overdose deaths: a medical examiner chart review. Apr 491–496
Tohen M, Case M, Trivedi MH, Thase ME, Burke SJ, Durell TM. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. Apr 451–462
Tohen M, Vieta E, González-Pinto A, Reed C, Lin D, European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Advisory Board. Baseline characteristics and outcomes in patients with first episode or multiple episodes of acute mania. Mar 255–261
Tohen M see Houston JP
Tomov T see Borges G
Topliss DJ see Ronaldson KJ
Torjesen PA see Berg AO
Torrent C see López-Jaramillo C
Torres IJ, DeFreitas VG, DeFreitas CM, Kauer-Sant'Anna M, Bond DJ, Honer WG, Lam RW, Yatham LN. Neurocognitive functioning in patients with bipolar I disorder recently recovered from a first manic episode. Sept 1234–1242
Tran Q-V see Kemp DE
Treves I see Levkovitz Y
Trevisi M see Manfredi G
Tripathi A see Jerrell JM
Trivedi MH see Freeman MP; Meyer RE; Stahl SM; Tohen M
Tsai C-H see Wu C-C
Tsai S-Y see Kuo C-J
Tsoh J see Lam SP
Tuisku K see Virtanen M
Tupin JP. Review of Torrey EF: *The Insanity Offense: How America's Failure to Treat the Seriously Mentally Ill Endangers Its Citizens.* June 810
Turecki G see Meyer RE
Turkin SR. Review of Beer MD, Pereira S, Paton C (eds): *Psychiatric Intensive Care, 2nd ed.* Mar 363–364
Turkoz I see Canuso CM
Uda H see Borges G
Utzinger L see Wilens TE
Vahia I see Zisook S
Vahtera J see Virtanen M
Valdovinos MG, Bailey L, Taylor SL. Examining risperidone use in those diagnosed with autism 1 year after FDA approval [letter]. May 651–652
Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. Randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. Oct 1336–1343
van Apeldoorn FJ, Timmerman ME, Mersch PPA, van Hout WJPJ, Visser S, van Dyck R, den Boer JA. Randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: treatment results through 1-year follow-up. May 574–586
van Balkom AJ see Thomaes K
van Balkom AJLM see van Oppen P
van den Brink W see van Zaane J
van der Meer JWM see The GKH
van Dyck R see van Apeldoorn FJ; van Mill JG; van Oppen P
van Haren NEM see Koolschijn PCMP
van Hout WJPJ see van Apeldoorn FJ
van Mill JG, Hoogendijk WJG, Vogelzangs N, van Dyck R, Penninx BWJH. Insomnia and sleep duration in a large cohort of patients with major depressive disorder and anxiety disorders. Mar 239–246
van Oppen P, van Balkom AJLM, Smit JH, Schuurmans J, van Dyck R, Emmelkamp PMG. Does the therapy manual or the therapist matter most in treatment of obsessive-compulsive disorder? a randomized controlled trial of exposure with response or ritual prevention in 118 patients. Sept 1158–1167
van Oppen P see Cuijpers P
van Os J see Jabben N
van Pelt J see van Reedt Dortland AKB
van Reedt Dortland AKB, Giltay EJ, van Veen T, van Pelt J, Zitman FG, Penninx BWJH. Associations between serum lipids and major depressive disorder: results from the Netherlands Study of Depression and Anxiety (NESDA). June 729–736
van Straten A see Cuijpers P
van Veen T see van Reedt Dortland AKB
van Wattum PJ. Review of Trivedi HK, Kershner JD: *Practical Child and Adolescent Psychiatry for Pediatrics and Primary Care.* July 963
van Zaane J, van den Brink W, Draisma S, Smit JH, Nolen WA. Effect of moderate and excessive alcohol use on the course and outcome of patients with bipolar disorders: a prospective cohort study. July 885–893
Veltman DJ see Thomaes K

Versavel M see Bowden CL
Vidarsdottir S, Vlug P, Roelfsema F, Frölich M, Pijl H. Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study. Sept 1205–1211
Vieta E. Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation. Suppl 2, 14–19
Vieta E. Individualizing treatment for patients with schizoaffective disorder. Oct e26
Vieta E. Long-term treatment of bipolar depression and other issues. Mar e07
Vieta E. Role of antidepressants in bipolar depression. Sept e21
Vieta E, de Arce R, Jiménez-Arriero MA, Rodriguez A, Balanzá V, Cobaleda S, SIN-DEPRES Group. Detection of subclinical depression in bipolar disorder: a cross-sectional, 4-month prospective follow-up study at community mental health services (SIN-DEPRES). Nov 1465–1474
Vieta E see Bowden CL; López-Jaramillo C; Rosa AR; Tohen M
Vigna NV see Hirschfeld RMA
Vincent KB see Garnier LM
Virtanen M, Batty GD, Pentti J, Vahtera J, Oksanen T, Tuisku K, Salo P, Terho K, Ahola K, Elovainio M, Kivimäki M. Patient overcrowding in hospital wards as a predictor of diagnosis-specific mental disorders among staff: a 2-year prospective cohort study. Oct 1308–1312
Visser S see van Apeldoorn FJ
Vlug P see Vidarsdottir S
Vogelzangs N, Kritchevsky SB, Beekman ATF, Brenes GA, Newman AB, Satterfield S, Yaffe K, Harris TB, Penninx BWJH, Health ABC Study. Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women. Apr 391–399
Vogelzangs N see van Mill JG
Vondrak PA see Faulkner LR
von Stralendorff I see Stübner S
Wade D see Gleeson JFM
Wagner KD. Anxiety in youth [introduction]. July 923
Wagner KD. Long-term treatment of bipolar disorder in children. Sept e23
Wagner KD. New developments [introduction]. Mar 312
Wagner KD. New findings on childhood mania [introduction]. Nov 1509–1510
Walker EF see Compton MT
Walsh BC see Woods SW
Wang PP see Bowden CL
Warren KR see Kelly DL
Waschbusch DA see Waxmonsky JG
Watanabe K see Suzuki T
Waxmonsky JG, Waschbusch DA, Pelham WE, Draganac-Cardona L, Rotella B, Ryan L. Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder. Nov 1535–1551
Weathers FW see Gilbertson MW
Wehring HJ see Kelly DL
Weinberg I, Ronningstam E, Goldblatt MJ, Schechter M, Wheelis J, Maltsberger JT. Strategies in treatment of suicidality: identification of common and treatment-specific interventions in empirically supported treatment manuals. June 699–706
Weisler RH. How do you choose a second-line treatment option for depression? Suppl 1, 21–26
Weisler RH see McElroy SL
Weiss MD, Gibbins C, Goodman DW, Hodgkins PS, Landgraf JM, Faraone SV. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. Apr 381–390
Weiss RD see Levy B; Winhusen TM
Weizman A see Ritsner MS
Welge JA see McElroy SL
West JC, Wilk JE, Rae DS, Muszynski IL, Rubio-Stipec M, Alter CL, Sanders KE, Crystal S, Regier DA. First-year Medicare Part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients. Apr 400–410
West JC see Mościcki EK
Westermeyer J. Review of MacGregor S (ed): *Responding to Drug Misuse: Research and Policy Priorities in Health and Social Care.* Dec 1703
Wheelis J see Weinberg I
White MA, Kalarchian MA, Masheb RM, Marcus MD, Grilo CM. Loss of control over eating predicts outcomes in bariatric surgery patients: a prospective, 24-month follow-up study. Feb 175–184
Wieck A, Kopparthi S, Sundaresh S, Wittkowski A. One-year outcome after preconception consultation in women with bipolar disorder [letter]. June 806
Wiederman MW see Sansone RA
Wiethoff K, Bauer M, Baghai TC, Möller H-J, Fisher R, Hollinde D, Kiermeir J, Hauth I, Laux G, Cordes J, Brieger P, Kronmüller K-T, Zeiler J, Adli M. Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. Aug 1047–1054
Wildgust HJ see Holt RIG
Wilens TE, Hammerness P, Martelon M, Brodziak K, Utzinger L, Wong P. Controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. May 548–556
Wilk JE see Mościcki EK; West JC
Wilkinson B see Sheehan DV
Williams DR see Borges G
Wing YK, Lam SP, Li SX, Zhang J, Yu MWM. Sleep-related eating disorder and zolpidem: an open interventional cohort study [letter]. May 653–656
Wing YK see Lam SP; Li SX
Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD, Leimberger JD, Lewis DF, Dorer EM. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. Dec 1680–1688
Wirz-Justice AM see Kasper S
Wish ED see Garnier LM
Wisner KL see Bogen DL; Freeman MP
Wittkowski A see Wieck A
Wong P see Wilens TE
Wong PWC see Fu K
Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. Apr 463–474
Wozniak P see Hirschfeld RMA
Wright EC see Cizza G
Wu C-C, Tsai C-H, Lu M-K, Chen C-M, Shen W-C, Su K-P. Theta-burst repetitive transcranial magnetic stimulation for treatment-resistant obsessive-compulsive disorder with concomitant depression [letter]. Apr 504–506
Wu TKY see Procyshyn RM
Wulff K see Kasper S
Xie D see Calarge CA
Yaffe K see Vogelzangs N
Yang R see Calabrese JR; Kane JM
Yang RR see Krystal AD
Yatham LN see Torres IJ
Yehuda R see Gilbertson MW
Yen S see Grilo CM; Sala R
Yen Y-C see Hou W-H
Yip AG, Carpenter LL. Transcranial magnetic stimulation for medication-resistant depression [ASCP Corner]. Apr 502–503
Yip PSF see Fu K
You J see Yuan Y

Youakim JM see Calabrese JR; Kane JM
Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M, EMBOLDEN I (Trial 001) Investigators. Double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). Feb 150–162
Young AH see McElroy SL; Procyshyn RM
Young D see Zimmerman M
Young IT see Zisook S
Youngstrom EA see Findling RL; Horwitz SM; Meyer RE
Yu E see Brooks AC
Yu H see Yuan Y
Yu MWM see Li SX; Wing YK
Yuan Y, Hou Z, Zhang Z, Bai F, Yu H, You J, Shi Y, Liu W, Jiang T. Abnormal integrity of long association fiber tracts is associated with cognitive deficits in patients with remitted geriatric depression: a cross-sectional, case-control study. Oct 1386–1390
Yuen HP see Henry LP
Yurgelun-Todd DA see Hooley JM
Zaghi S see Boggio PS
Zarate CA Jr see DiazGranados N; Salvadore G
Zayed A see Ritsner MS
Zeiler J see Seemüller F; Wiethoff K
Zeugmann S, Quante A, Heuser I, Schwarzer R, Anghelescu I. Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome. Aug 1007–1016
Zhang J see Lam SP; Li SX; Wing YK
Zhang M. Major depressive disorder treatment guidelines in China. Suppl E1, e06
Zhang M see Nutt DJ
Zhang Z see Yuan Y
Zimmerman B see Calarge CA
Zimmerman M, Chelminski I, Young D, Dalrymple K. Clinically Useful Anxiety Outcome Scale. May 534–542
Zimmerman M, Galione JN, Attiullah N, Friedman M, Toba C, Boerescu DA, Ragheb M. Underrecognition of clinically significant side effects in depressed outpatients. Apr 484–490
Zimmerman M, Galione J. Psychiatrists' and nonpsychiatrist physicians' reported use of the *DSM-IV* criteria for major depressive disorder. Mar 235–238
Zimmerman M, Galione JN, Ruggero CJ, Chelminski I, Young D, Dalrymple K, McGlinchey JB. Screening for bipolar disorder and finding borderline personality disorder. Sept 1212–1217
Zimmerman M, Ruggero CJ, Chelminski I, Young D. Psychiatric diagnoses in patients previously overdiagnosed with bipolar disorder. Jan 26–31
Zimmerman M see Gaudiano BA
Zhang M see Nutt DJ
Zink M, Marquardt L, Sartorius A. Quetiapine-associated increase of triglycerides: a case report. Nov 1554–1555
Zisook S, Kasckow JW, Lanouette NM, Golshan S, Fellows I, Vahia I, Mohamed S, Rao S. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. July 915–922
Zisook S, Reynolds CF III, Pies R, Simon N, Lebowitz B, Madowitz J, Tal-Young I, Shear MK. Bereavement, complicated grief, and *DSM*, part 1: depression [ASCP Corner]. July 955–956
Zisook S, Simon NM, Reynolds CF III, Pies R, Lebowitz B, Young IT, Madowitz J, Shear MK. Bereavement, complicated grief, and *DSM*, part 2: complicated grief [ASCP Corner]. Aug 1097–1098
Zitman FG see Lamers F; van Reedt Dortland AKB

Biological Therapies in Psychiatry

Alan J. Gelenberg, M.D.

AN INDEPENDENT VOICE.
NO ADS.
NO PHARMACEUTICAL SUPPORT.

"With time as tight as it is, I really appreciate the sheer volume of material that you review and summarize for us. You provide a tremendous service to busy clinicians like me and those we serve. Thanks again!"
- J. Rutherford, M.D.

- ONLINE ACCESS
- SEARCHABLE ARCHIVES
- CME CREDIT

SPECIAL OFFER FOR NEW SUBSCRIBERS
15 months for the price of 12!
(Enter promotion code JCP549 or mention when you call to order.)

ASCP American Society of Clinical Psychopharmacology | Partners in Education in Psychopharmacology

VISIT BTPNEWS.COM OR CALL (800) 700-9589 FOR A SAMPLE ISSUE AND RATES.